NHP PBMC Model Development Service

Are you encountering translational challenges in toxicology, such as unpredictable Cytokine Release Syndrome (CRS) or difficulties in identifying druggable targets within non-human primates (NHP) models? Creative Biolabs' NHP PBMC Model Development Service at Creative Biolabs is designed to bridge this gap. We employ advanced high-content screening (HCHT) and functional ex vivo assays to generate robust, predictive data, thereby de-risking your path to clinical trials.

Introduction

With their close physiological and genetic similarity to humans, NHPs offer exceptional predictive power as preclinical models. NHP-derived peripheral blood mononuclear cells (PBMCs), containing critical immune cell populations, accurately model human immune responses and deliver more reliable data for drug safety and efficacy studies than other systems. Our NHP PBMC Model Development Service bridges the gap from discovery to clinic by producing high-confidence in vitro data, helping you to de-risk development and accelerate critical decisions.

Fig.1 NHP PBMC model for predictive immune response analysis in B. mallei infection.¹

NHP PBMC Model Development Service at Creative Biolabs

Creative Biolabs' NHP PBMC Model Development Service establishes the rigorously validated connection between preclinical NHP models and clinical outcomes in humans, significantly mitigating the risks associated with translational failure. We support your program through the development of customized, sophisticated ex vivo assays specifically designed to align with your compound's unique mechanism of action (MoA), which ensures that the resulting data are not only quantitative and reproducible, but also highly predictive of clinical performance.

What We Can Offer

As a specialist in immunology and translational models, Creative Biolabs provides an integrated suite of services built around our high-quality NHP PBMC platform. Here is a detailed overview of our core offerings:

Our Service Process

Required starting materials:

• NHP Sample Type or Species.
• Targeted Readouts: Specific biomarkers or cell subsets of interest.
• Compound Properties.

Key Steps Involved:

Final Deliverables:

• Detailed Method Validation Report including species cross-reactivity data.
• Data Package including raw files and statistical analysis.

Key Advantages

• Translational Confidence from Model to Model: We de-risk your decision-making across different biological models. Our specialized assay validation guarantees that your immunotoxicity and efficacy data are directly comparable, whether generated in NHP PBMCs or rapidly evolving humanized systems.
• Cell Sourcing that Powers Precision: We remove a major confounding variable by providing premium, well-characterized naïve NHP PBMCs. This foundational quality control ensures that the baseline variability in your complex immune assays is minimized, revealing clear, actionable results.

FAQ

Why Choose Us?

Leveraging over 20 years of leadership in complex biological modeling and diagnostics, we translate our deep expertise into a highly predictive NHP PBMC Service for your program. We provide scientifically-validated solutions, focused on de-risking your development path through evidence, not assumptions.

Customer Reviews

"Using Creative Biolabs' NHP PBMC Model Development Service in our research has significantly facilitated the identification of novel therapeutic targets in infectious disease models. Their LC-MS/MS proteomics confirmed Ezrin as a key regulatory node, providing a clear path for drug modulation."— S**a*ah B.

"The strategic integration of proteomics with standard assays, enabled by Creative Biolabs' NHP PBMC model development service, was transformative for our project. It uncovered a novel inflammatory protein target, revealing a completely new therapeutic pathway that traditional cytokine panels had failed to detect." S. G. W**.

How to contact us?

Creative Biolabs is the premier provider of NHP PBMC model development, harnessing advanced primate biology to generate high-content, actionable data. Contact our specialists to discuss your project requirements, custom solutions, and to request a technical validation package.

Reference

1. Chiang, Chih-Yuan et al. "Proteomic Analysis of Non-human Primate Peripheral Blood Mononuclear Cells During Burkholderia mallei Infection Reveals a Role of Ezrin in Glanders Pathogenesis." Frontiers in microbiology vol. 12 625211. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2021.625211.